Exicure

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based in Chicago, IL.

SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Ticker:
XCUR
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Illinois
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Cavrotolimod (TLR9 Agonist)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Exicure, Inc.